Overview of the 2011 Work Programme Paul Griffiths Scientific committee meeting, Lisbon, November...

Overview of the 2011 Work Programme

Paul Griffiths

Scientific committee meeting, Lisbon, November 2010

2

Overview

• Three-year strategy (2010–2012) will be implemented through 3 annual work plans, 2011 WP is the 2’nd

• Heart of the agency work remains:• State of the art review of the drug phenomenon• Maintaining an up to date reference point on drugs• Providing ongoing support to EU institution and

Member states for monitoring and implementing the EU strategy and action plan

2011 WP

Highlights

Core activities

Key indicators

Monitoring responses

Transversal analysis

Supplyreduction

3

2011 focus

• Ensuring European system fits for the purpose & remaining responsive to developments

• Further dissemination of best practice• Developing information sources in supply

reduction• Support the evaluation of the EU strategy and

action plan• Focus on polydrug use, combined analysis,

policy-relevance analysis• Dissemination and valorising EMCDDA

findings

2011 WP

Highlights

Core activities

Key indicators



Supplyreduction

4

State of the art review

• Preparation of the Annual report package• Efficient and methodologically sound data

input, management and processing• Top level strategic review of data

collected and appropriateness of the instruments used

• Continue development of statistical bulletin

• Further technical development of FONTE and data warehouse

2011 WP

Highlights

Core activities

Key indicators



Supplyreduction

5

Remain methodologically sound

• Efficient collection and analysis of the KIs• Maintaining and strengthen network• Increase quality and comparability

• Better integration of youth survey (GPS)• Final stage of rationalisation of TDI• Broadening scope of PDU• Update protocol of DRID• Improve tools for mortality cohort data collection• New data lab workshop (GPS, mortality registries)

2011 WP

Highlights

Core activities

Key indicators



Supplyreduction

6

Support to EC and rationalise data collection

• Support to the Council recommendation on prevention and reduction of health related harm

• Investigate and develop models for collecting data on:• Opiates substitution treatment• GPs• Low-threshold agencies

• Cochrane systematic review on media campaigns

• Conceptual framework for coherent set of response indicators

2011 WP

Highlights

Core activities

Key indicators



Supplyreduction

7

Cross analysis and CUPs

2011 WP

Highlights

Core activities

Key indicators



Supplyreduction

• Treatment coverage in subgroups of users• Alcohol cannabis connections• Polydrug use• Drugs and driving

• CUP treatment: coherent supportive and scientifically sound approach for monitoring treatment in Europe

• CUP prison: scale up monitoring of prison setting• CUP modelling: identify and support policy relevant

analyses

8

Development and adoption of indicators 2011 WP

Highlights

Core activities

Key indicators



Supplyreduction

• Improving understanding of Europe’s specialised police units

• 3 expert groups (drug markets, drug-related crime, drug supply reduction)

• Second technical conference on DSSR

9

Combine EWS and emerging trends

2011 WP

New drugs

Policy

Goodpractice

Main outputs

• Implement efficiently Council Decision (EWS)• Assist in assessment of the Council decision• Structured internet monitoring• Further develop links with forensic/toxicology• Trend-spotting- develop integrated approach for

monitoring emerging trends• Initial implementation of monitoring of misuse of

medicinal products• Multidisciplinary project on monitoring illicit drugs

in waste water

10

Improving Europe’s capacity to monitor and evaluate policies 2011 WP

New drugs

Policy

Goodpractice

Main outputs

• Review and develop framework for drug policy analysis

• Study on drug policy advocacy groups• Contribute to the evaluation of the EU

strategy and action plan• And provide appropriate support to the

commission in this area• Model the impact on unemployment on

drug issues

11

Expend BPP and promote cooperation with scientific community 2011 WP

New drugs

Policy

Goodpractice

Main outputs

• Support EU project on standard and guidelines for interventions harm reduction and social rehabilitation

• Expend and continue promoting best practice in Europe

• Promote and facilitate EU research on drug issues

• Net work with scientific community and relevant organisations

12

• Annual report package

• EU drug strategy• Scientific Monograph• Insights• Manuals• Drug policy profiles• Drugs in Focus• Thematic papers• Joint publications• Online tools• Articles

• Annual report• Statistical bulletin• Selected issues (treatment

guidelines, cost of treatment, mortality)

2011 WP

New drugs

Policy

Goodpractice

Main outputs

13



• Situation and responses review since 2005

2011 WP

New drugs

Policy

Goodpractice

Main outputs • EMCDDA public website• Best practice portal• ELDD• Country intervention

profiles

14



• New groups of psychoactive substances

2011 WP

New drugs

Policy

Goodpractice

Main outputs• European ecstasy market

(Europol)• Guidance on prevention of

infections among IDus (ECDC

15



2011 WP

New drugs

Policy

Goodpractice

Main outputs• Emerging drug trends case

study• Drug couriers• New methods for cross

analysis of prevention trials• Drug user perspective in

quitting drug use, etc….

• Cannabis market and production

• Heroin-assisted treatment• Models of dependency and

compulsive behaviour

16



2011 WP

New drugs

Policy

Goodpractice

Main outputs

• DRID protocol• Mortality cohort protocol• Guidelines for evaluation

of national drug strategies

• Responding to psychoactive substances

• Minimum quality standard of interventions

• Drug-related research• Khat

17



2011 WP

New drugs

Policy

Goodpractice

Main outputs

• New series of national drug policy profiles

Questions and discussion

Overview of the 2011 Work Programme Paul Griffiths Scientific committee meeting, Lisbon, November...

Documents

Transcript of Overview of the 2011 Work Programme Paul Griffiths Scientific committee meeting, Lisbon, November...